Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
shengbaikeli
- Development stage
- Phase 4
- Lead developer
- First People's Hospital of Lianyungang City
- Administration
- Oral
01
Overview
Shengbaikeli is a Traditional Chinese Medicine (TCM) granule formulation developed as a hospital preparation by The First People’s Hospital of Lianyungang. It is primarily indicated for the treatment of grade I–II leukopenia in patients with malignant tumors following antitumor therapy (chemotherapy or radiotherapy). Additionally, it is used to improve cancer-related fatigue and the overall quality of life in this patient population. As a hematopoietic stimulant, it aims to increase white blood cell counts, and its efficacy is often evaluated in comparison to other established TCM treatments like Diyushengbai Tablets.
- Other names
- Sheng Bai Ke Li升白颗粒Sheng-Bai Granules
Beyond the preview
Go deeper on shengbaikeli.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on shengbaikeli.